Immunai said the new funding will allow it to expand its genomics capabilities from the observational to the functional, including reprogramming immune cells as well as prioritizing and validating targets . . .
- Neurological Disorders
- Alzheimers
- Artificial Intelligence
- Autoimmune Disorders
- Cancer
- Virology
- Coronavirus
- Information Management
- Data Analysis
- Data Management
- GEN Edge
- OMICs
- Genomics
- Single Cell Technology
- Single-Cell Genomics
Immunai Expands from Observational to Functional Genomics
Developer of AI-based single-cell immunology database focuses on reprogramming immunity with $60M Series A financing
[L.-R.] Luis Voloch, PhD., Chief Technology Officer of Immunai, and Noam Solomon, PhD, the company’s CEO and Co-founder. Immunai has completed a $60 million Series A financing that it says will enable its expansion into functional genomics, with the goal of improving how it integrates artificial intelligence (AI) and single-cell multi-omics at scale to help its biopharma and healthcare partners better detect, diagnose, and treat disease. [Immunai]
